Any attendees who feel ill, regardless of their symptoms, should not attend this event. Please note attendance at any public event increases the risk of contracting COVID-19 or other airborne illness, and attendees assume all risk associated with attendance. Ongoing updates on Physicians' Education Resource®'s plans related to this event, including education and programming, will continue to be available at. As we develop the programming for this activity, Physicians' Education Resource® will follow the guidelines to optimize health and conditions for attendees during the event. We are dedicated to remaining informed about the ongoing COVID-19 pandemic at the global and local levels. Physicians' Education Resource®’s top priority is ensuring the safety and security of our attendees, staff, and operational personnel. ![]() To earn an additional 4.0 AMA PRA Category 1 Credits™, be sure to attend the CAR T Preconference Workshop. This dynamic congress will inspire participants to reflect on and share the new information they have learned, and to apply these new practices in the clinical setting, with the ultimate goal of improving patient outcomes. These sessions will provide attendees with the opportunity to explore some of the most challenging clinical situations in the management of hematologic malignancies-treatment scenarios with multiple potential approaches. Interspersed throughout the meeting are sessions of Medical Crossfire®, a nationally recognized healthcare communication platform for debate, discussion, and peer exchange. Finally, we will continue to provide expert opinion on how the value-based landscape will impact your clinical practice. Proactive measures to mitigate and manage treatment-related toxicities associated with new cellular therapies will also be discussed. Our faculty will distill practice-changing evidence and recommend how to put this information into clinical context, so that you may apply the latest evidence to real-world patient-care scenarios. ![]() This engaging and highly interactive meeting will provide ample opportunity for attendees to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and benign hematologic malignancies. Next, sessions on Friday, Saturday, and Sunday will focus on methods to apply state-of-the-art treatment strategies in your clinical practice setting. First, a full afternoon session on Thursday, February 24, 2022, will be dedicated to addressing advances in CAR T-cell therapy for hematologic malignancies, as well as other immune-based therapies and strategies to overcome treatment resistance. We are pleased to continue expanded coverage on chimeric antigen receptor (CAR) T cells and other immune-based therapies in 2022. ![]() Now in its 27th year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies with the practical tools to translate emerging data into the best therapy for their patients, to personalize care according to patient and tumor characteristics, and to apply novel treatment strategies to improve patient outcomes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |